191 related articles for article (PubMed ID: 36288512)
1. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic
Brastianos PK; Twohy EL; Gerstner ER; Kaufmann TJ; Iafrate AJ; Lennerz J; Jeyapalan S; Piccioni DE; Monga V; Fadul CE; Schiff D; Taylor JW; Chowdhary SA; Bettegowda C; Ansstas G; De La Fuente M; Anderson MD; Shonka N; Damek D; Carrillo J; Kunschner-Ronan LJ; Chaudhary R; Jaeckle KA; Senecal FM; Kaley T; Morrison T; Thomas AA; Welch MR; Iwamoto F; Cachia D; Cohen AL; Vora S; Knopp M; Dunn IF; Kumthekar P; Sarkaria J; Geyer S; Carrero XW; Martinez-Lage M; Cahill DP; Brown PD; Giannini C; Santagata S; Barker FG; Galanis E
J Clin Oncol; 2023 Jan; 41(3):618-628. PubMed ID: 36288512
[TBL] [Abstract][Full Text] [Related]
2. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
3. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
[TBL] [Abstract][Full Text] [Related]
4. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
5. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Soria JC; Gan HK; Blagden SP; Plummer R; Arkenau HT; Ranson M; Evans TR; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Dean E; Brown J; Gibson D; Peddareddigari V; Murray S; Nebot N; Mazumdar J; Swartz L; Auger KR; Fleming RA; Singh R; Millward M
Ann Oncol; 2016 Dec; 27(12):2268-2274. PubMed ID: 27733373
[TBL] [Abstract][Full Text] [Related]
6. Innovative treatments for meningiomas.
Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
[TBL] [Abstract][Full Text] [Related]
8. NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.
Vasan V; Dullea JT; Devarajan A; Ali M; Rutland JW; Gill CM; Kinoshita Y; McBride RB; Gliedman P; Bederson J; Donovan M; Sebra R; Umphlett M; Shrivastava RK
J Neurooncol; 2023 Jan; 161(2):309-316. PubMed ID: 36436149
[TBL] [Abstract][Full Text] [Related]
9. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index.
Teranishi Y; Okano A; Miyawaki S; Ohara K; Ishigami D; Hongo H; Dofuku S; Takami H; Mitsui J; Ikemura M; Komura D; Katoh H; Ushiku T; Ishikawa S; Shin M; Nakatomi H; Saito N
Acta Neuropathol Commun; 2022 May; 10(1):76. PubMed ID: 35570314
[TBL] [Abstract][Full Text] [Related]
12. NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study.
Buccoliero AM; Castiglione F; R Degl'Innocenti D; Gheri CF; Garbini F; Taddei A; Ammannati F; Mennonna P; Taddei GL
Neuropathology; 2007 Feb; 27(1):36-42. PubMed ID: 17319281
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression.
Cain SA; Pope B; Mangiola S; Mantamadiotis T; Drummond KJ
BMC Cancer; 2023 Mar; 23(1):216. PubMed ID: 36882706
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy and targeted therapies for meningiomas: what is the evidence?
Graillon T; Tabouret E; Chinot O
Curr Opin Neurol; 2021 Dec; 34(6):857-867. PubMed ID: 34629433
[TBL] [Abstract][Full Text] [Related]
16. Crispr/Cas-based modeling of NF2 loss in meningioma cells.
Waldt N; Kesseler C; Fala P; John P; Kirches E; Angenstein F; Mawrin C
J Neurosci Methods; 2021 May; 356():109141. PubMed ID: 33753124
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas.
Hrachova M; Nguyen ENT; Fu BD; Dandekar MJ; Kong XT; Cadena G; Hsu FPK; Billimek J; Taylor TH; Bota DA
Front Neurol; 2020; 11():373. PubMed ID: 32435228
[No Abstract] [Full Text] [Related]
18. A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.
Brown NF; Williams M; Arkenau HT; Fleming RA; Tolson J; Yan L; Zhang J; Singh R; Auger KR; Lenox L; Cox D; Lewis Y; Plisson C; Searle G; Saleem A; Blagden S; Mulholland P
Neuro Oncol; 2018 Nov; 20(12):1634-1642. PubMed ID: 29788497
[TBL] [Abstract][Full Text] [Related]
19. NF2 mutations in secretory and other rare variants of meningiomas.
Hartmann C; Sieberns J; Gehlhaar C; Simon M; Paulus W; von Deimling A
Brain Pathol; 2006 Jan; 16(1):15-9. PubMed ID: 16612978
[TBL] [Abstract][Full Text] [Related]
20. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation.
Peyre M; Stemmer-Rachamimov A; Clermont-Taranchon E; Quentin S; El-Taraya N; Walczak C; Volk A; Niwa-Kawakita M; Karboul N; Giovannini M; Kalamarides M
Oncogene; 2013 Sep; 32(36):4264-72. PubMed ID: 23045274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
